EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis

Marek Peterka, Martin Valis, Ondrej Soucek, Jan Krejsek, Lukáš Sobisek, Ilona Sejkorova, Blanka Klimova, Pavel Stourac, Zbysek Pavelek, Michal Novotny

European Neurology · 2023

DOI: 10.1159/000532022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Neurology, 2023. Verfasst von Marek Peterka und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzen, Czechia. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations.

Methods

Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD).

Results

A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10–20%.

Conclusion

Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingFemaleHumansGlatiramer AcetateInterferon beta-1aInterferon-betaPeptidesImmunity, Innate

Stichwörter der Autor:innen

Glatiramer acetateInnate immunityInterferon beta-1aMonocytesMultiple sclerosis

Substanzen

Glatiramer AcetateInterferon beta-1aInterferon-betaPeptides

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzen, Czechia.
  • Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia.
  • Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia.
  • Department of Neurology, Masaryk University, Faculty of Medicine and University Brno, Brno, Czechia.

Zitieren

APA

Peterka, M., Valis, M., Soucek, O., Krejsek, J., Sobisek, L., Sejkorova, I., Klimova, B., Stourac, P., Pavelek, Z., & Novotny, M. (2023). Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis. European Neurology. https://doi.org/10.1159/000532022

Vancouver

Peterka M, Valis M, Soucek O, Krejsek J, Sobisek L, Sejkorova I, et al. Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis. European Neurology. 2023. doi:10.1159/000532022

BibTeX
@article{Peterka2023,
  author = {Peterka, Marek and Valis, Martin and Soucek, Ondrej and Krejsek, Jan and Sobisek, Lukáš and Sejkorova, Ilona and Klimova, Blanka and Stourac, Pavel and Pavelek, Zbysek and Novotny, Michal},
  title = {Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis},
  journal = {European Neurology},
  year = {2023},
  doi = {10.1159/000532022}
}
Kostenlos starten →